CClinicalTrials.gg
CompletedNCT06409000Updated Feb 24, 2026

Evaluation of 3D Surface Scanning for Virtual-CT Based Radiation Therapy Treatment Planning

An observational study in Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Mayo Clinic · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
26
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates if three dimensional (3D) surface images can be used instead of the standard computed tomography (CT) scans for treatment planning in electron radiation therapy. 3D scanning has previously been used by several groups to design patient-specific devices to be 3D printed, and as has shown excellent agreement with CT obtained surfaces. Using 3D surface imaging instead of x-ray based CT, benefits include: no ionizing radiation used to produce images, shorter time between patient consultation and treatment, and ability to produce and evaluate patient-specific devices for electron therapy earlier in the treatment planning process. This study may help researchers learn how 3D surface scanning may be used to produce a virtual CT image of patient surfaces, and accurately replace traditional planning CT for treatment planning of electron based radiation therapy.

Read the detailed description

PRIMARY OBJECTIVES:

I. Develop and benchmark the necessary software to convert a 3D scan to a virtual CT.

II. Compare the spatial accuracy of virtual CTs from 3D scans to the planning CT.

III. Compare radiation treatment plans based on the virtual CTs from aim 2 to treatment plans based on the actual planning CTs.

OUTLINE: This is an observational study.

Patients undergo 3D surface scans on study. Patient's medical records are also reviewed on study.

02

Conditions studied

  • Hematopoietic and Lymphatic System Neoplasm
  • Malignant Solid Neoplasm
03

In context

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients being treated with electron radiation therapy at Mayo Clinic.

Inclusion criteria

  • Adults (18 years old or older)
  • Capable of consent
  • Receiving electron therapy and a planning CT scan
  • Consent to two 3D surface scans of treatment area

Exclusion criteria

Exclusion Criteria:

  • Pediatric patients
  • Mentally incapable of study consent
  • Receiving electron radiation for a breast cancer boost
  • Receiving electrons for total skin electron therapy
  • Patients with epilepsy or other seizure disorders
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
26 participants (actual)
Patient registry
No

Groups and cohorts

  • Observational (3D surface scans, medical records)

    Patients undergo 3D surface scans on study. Patient's medical records are also reviewed on study.

    Other: Electronic Health Record Review · Procedure: Three-Dimensional Imaging

Interventions

  • OtherElectronic Health Record Review

    Medical records reviewed

  • ProcedureThree-Dimensional Imaging

    Undergo 3D surface scans

    Also known as: 3-D Imaging, 3-Dimensional Imaging, 3D Imaging, Medical Imaging, Three Dimensional

06

What researchers measure

Primary outcomes

  1. Dose distribution agreement between virtual and planning computed tomography (CT) datasets

    The various three dimensional (3D) scans and CTs of the phantoms will be qualitatively assessed for agreement and accuracy to determine best practice, but there will be no statistical significance tested for. Will be conducted entirely on inanimate, plastic, anthropomorphic models (phantoms).

    Time frame: Up to 2 months

  2. Geometric agreement between virtual and planning CT datasets

    Will test for distance to agreement differences between 3D scans taken at different time points (consultation, simulation, and treatment).

    Time frame: Up to 2 months

  3. Geometric agreement between 3D scans taken at different time points

    Various dose metrics will be extracted from each of the three types of dose distribution: the ground truth CT based dose distribution, the 3D scan based virtual CT dose distributions, and the flat water phantom based dose distributions. Paired statistical tests will be used for each metric to test for significant differences between the various methods used to calculate the dose distributions.

    Time frame: Up to 2 months

07

Study locations

1 site
  • Mayo Clinic in Arizona
    Scottsdale, Arizona 85259, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06409000
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Jan 19, 2021
Primary completion
Feb 5, 2026
Completion
Feb 5, 2026
Last update
Feb 24, 2026

Study contacts

Daniel P. Harrington, MS
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion